

December 1, 2023

**BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <u>Scrip Code: 532531</u> **The National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>Scrip code: STAR</u>

Dear Sirs,

## Sub: Strides associate company - Stelis Biopharma announces closure of its transaction with Syngene International Limited

In continuation to our announced transaction with Syngene dated 4 July 2023, Stelis Biopharma, an associate company of Strides would like to provide the following updates :

- 1. Stelis & Syngene have executed the final agreements to transfer its Unit 3 multi-modal facility in Bengaluru to Syngene with the following modifications:
  - Gross consideration adjusted from INR 7,020 Million to INR 6,170 Million a reduction of INR 850 Million. This is on account of amongst other things Stelis retaining 10 single use of 2KL (20,000 litres) reactors not currently installed in the facility.

This will support our increased focus for Mammalian Drug Substance opportunities in the CDMO space. With its current installed capacity of 8,000 litres, the near term expanded capacity at 28,000 litres will make Stelis a significant player in the space.

- 2. Stelis has received today (1 December, 2023) a payment of INR 3,950 Million and the balance amount shall be received on completion of certain post-closing actions and final adjustments, if any which is expected in December 2023.
- 3. The proceeds received today along with cash and cash equivalents has been deployed to repay Stelis' lenders to the extent of INR 4,200 Million.
- 4. The above payment has also resulted in the release/ reduction of corporate guarantees issued by Strides on behalf of Stelis by circa INR 8,000 Million.



We request that you take the above on record.

Thanks & Regards, For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary ICSI Membership No. A30515